NIH-funded research R01 grant

How gut bacterial indoles affect intestinal inflammation and healing

Official title: Indole dysbiosis and mucosal inflammation

Funded at University of Colorado Denver · NIH-11262908 · Data updated 2026-11-12

This project looks at whether small molecules made by gut bacteria from dietary tryptophan, called indoles, help protect and heal the gut lining in people with Crohn's disease and ulcerative colitis.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Colorado Denver
NIH-funded
Lab location1 site (Aurora, UNITED STATES)
Project startJune 1, 2012
Project endDecember 31, 2028
Funding year2026
Award (this year)$544,626
NIH project number5R01DK095491-13
Project IDNIH-11262908 on NIH RePORTER

Who could benefit from this research

Could help

People with active inflammatory bowel disease (Crohn's disease or ulcerative colitis), especially those with mucosal inflammation or poor wound healing, would be the most relevant candidates.

Less likely to help

Patients without IBD or whose disease is driven by non-microbial mechanisms may not directly benefit from this research.

What this research studies

From a patient perspective, the team will study how indoles produced by gut microbes interact with immune proteins and enzymes that can damage the intestinal lining during flares. They will focus on a neutrophil enzyme called myeloperoxidase (MPO) to see if indoles change how much bystander tissue damage occurs and how well wounds repair. The work uses a mix of lab studies with human-derived samples and model systems to map the indole–MPO pathway and test whether altering it improves barrier function. Results could point to drug targets or strategies to help the inflamed gut heal better.

Why it matters

Potential benefit: If successful, the work could lead to new treatments that protect the gut lining and speed healing during IBD flares.

How similar studies have gone: Prior research supports that indoles can help gut barrier health, but specifically targeting the indole–myeloperoxidase interaction is a newer approach with limited clinical testing so far.

Where this research is happening

  • University of Colorado Denver
    Aurora, United States
    Active

Researchers

  • Principal investigator: Colgan, Sean P — University of Colorado Denver
  • Study coordinator: Colgan, Sean P

Related research

Other NIH-funded projects on the same topics.

  • Microbial Dysbiosis and Its Role in Pancreatic Cancer

    A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.

    NIH research Northwestern University · Chicago, United States · NIH-11624054

  • From Symbiosis to Dysbiosis: How Resolving Inflammation Could Restore Your Mouth’s Balance

    This grant explores how turning off the harmful inflammation in periodontitis and promoting natural healing could help restore the mouth’s healthy balance.

    NIH research Ada Forsyth Institute, INC. · Somerville, UNITED STATES · NIH-11621747

  • Antibiotics, gut health, and skin reactions in kids

    A small study in children will look at whether antibiotic use and gut bacteria play a role in hives and related symptoms that children sometimes get after antibiotics.

    NIH research Cincinnati Childrens Hosp Med Ctr · Cincinnati, United States · NIH-11603169

  • Novel therapeutic to protect the gut after radiation

    A new GI-directed treatment given after radiation exposure may reduce gut damage and improve survival in people exposed to high-dose radiation.

    NIH research Columbia University Health Sciences · New York, United States · NIH-11572662

  • A new GI-focused treatment to reduce radiation damage after exposure

    A potential GI-targeted therapy given after radiation exposure may help protect the gut and improve survival in people affected by radiation injuries.

    NIH research Columbia University Health Sciences · New York, United States · NIH-11572658

  • How a mouth bacterium might fuel gum disease and heart risk

    A small study will look at how a bacterium in the mouth that makes a reactive chemical (methylglyoxal) could drive gum inflammation and changes in the mouth’s bacteria, possibly linking to heart disease.

    NIH research State University of New York at Buffalo · Amherst, United States · NIH-11564245

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.